Second Quarter 2023 Financial Results Conference Call Apellis Participants CEDRIC F RANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM T OWNSEND ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other jur ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yig ...

First Quarter 2023 Financial Results Conference Call May 4, 2023 Apellis Participants C E D R I C F R AN C O I S , M . D . , P h . D . Co-Founder, President & Chief Executive Officer AD A M T O W N S E N D Chief Commercial Officer C AR O L I N E B AU M A L , M . D . Chief Medical Officer T I M O T H Y S U L L I VAN Chief Financial Officer 2 APELLIS PROPRIETARY INFORMATION / FOR APELLIS USE ONLY Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well ...

Financial Performance - For the three months ended March 31, 2023, the company generated $18.4 million in net product revenue from sales of SYFOVRE and $20.4 million from EMPAVELI, totaling $38.8 million in net product revenue [128][130]. - Product revenue for Q1 2023 reached $38.8 million, a 220% increase from $12.1 million in Q1 2022, driven by EMPAVELI and SYFOVRE sales [174]. - Total revenue for Q1 2023 was $44.8 million, up 212% from $14.4 million in Q1 2022 [173]. - The company incurred net losses of $177.8 million for the three months ended March 31, 2023, compared to $138.9 million for the same period in 2022, with an accumulated deficit of $2.5 billion [137]. - Net loss for Q1 2023 was $177.8 million, a 28% increase from a net loss of $138.9 million in Q1 2022 [173]. - Interest income surged to $5.4 million in Q1 2023, compared to $0.1 million in Q1 2022, reflecting higher money market rates [181]. Cash and Funding - As of March 31, 2023, the company had cash and cash equivalents of $765.1 million, which is expected to fund operations at least into the first quarter of 2025 [136]. - The company expects to fund operating expenses and capital expenditures at least into the first quarter of 2025, based on current cash and anticipated sales [203]. - The company has financed operations through $1.6 billion in net proceeds from public offerings and $535.8 million from convertible notes [186]. - Net cash used in operating activities was $177.6 million for the three months ended March 31, 2023, compared to $111.6 million for the same period in 2022 [197][199]. - Net cash provided by financing activities was $391.1 million during the three months ended March 31, 2023, primarily from a follow-on common stock offering [200][201]. - The company may need to seek additional funding to support ongoing commercialization and development activities [205]. Expenses and Costs - The company anticipates significant increases in expenses related to commercialization and ongoing clinical trials [138]. - Research and development expenses are expected to increase as product candidate development programs progress, with costs primarily related to employee expenses and third-party agreements [164][167]. - General and administrative expenses are anticipated to increase to support ongoing research and development activities and potential commercialization of product candidates [168]. - Research and development expenses increased by 21% to $110.0 million in Q1 2023, compared to $90.9 million in Q1 2022 [179]. - General and administrative expenses rose by 99% to $102.1 million in Q1 2023, up from $51.2 million in Q1 2022 [180]. - Cost of sales increased to $7.8 million in Q1 2023 from $1.2 million in Q1 2022, primarily due to higher product sales volume [176]. - Significant commercialization expenses are anticipated for the product manufacturing, marketing, and sales of EMPAVELI and SYFOVRE [202]. Product Development and Collaborations - The company launched SYFOVRE in the United States in March 2023, targeting a market of over one million people affected by geographic atrophy [128]. - The company expects a decision from the European Medicines Agency on the marketing authorization application for intravitreal pegcetacoplan in early 2024 [129]. - The company is co-developing systemic pegcetacoplan for five indications in collaboration with Sobi, including C3 glomerulopathy and amyotrophic lateral sclerosis [132]. - The company plans to advance additional product candidates into clinical development in 2023, including an oral alternative pathway inhibitor and a novel compound for GA and wet AMD [134]. - The company has a development funding agreement with SFJ Pharmaceuticals Group, which includes potential payments of up to $60.0 million upon achieving specified development milestones [139]. - The company received a total of $250.0 million upfront from Sobi under a collaboration agreement, with potential milestone payments of up to $915.0 million and reimbursement of up to $80.0 million in development costs [158]. - The company earned a $50.0 million payment from Sobi related to the first regulatory and reimbursement milestone in Europe in March 2022 [159]. Debt and Liabilities - The company recognized a total of $149.7 million in net debt increase and net equity reduction upon adopting ASU 2020-06, which included reclassifications from equity to debt for the Convertible Notes [151]. - The effective interest rate used to determine the liability component of the 2019 and 2020 Convertible Notes was 10.5%, resulting in liabilities of $145.1 million and $204.5 million for the respective notes [150]. - The company entered into exchange agreements in January 2021, July 2021, and July 2022, resulting in a reduction of net debt by $122.8 million, $197.0 million, and $96.8 million respectively, and an increase in shares outstanding by 3,906,869, 5,992,217, and 3,027,018 shares [152][155][156]. - The company may redeem all or a portion of the Convertible Notes for cash on or after September 20, 2023, if the last reported sale price of common stock has been at least 130% of the conversion price for at least 20 trading days [148]. Market and Revenue Recognition - Product revenues are derived from sales of EMPAVELI and SYFOVRE in the United States, with revenue recognized upon satisfying performance obligations [160][161]. - Licensing and other revenue for Q1 2023 was $6.0 million, up from $2.3 million in Q1 2022, driven by product supply and royalty revenue from Sobi [175]. - The company expects continued impact on cost of sales as remaining pre-FDA approval inventory is sold [178]. - The company is closely monitoring credit risk related to deposits, particularly following the closure of Silicon Valley Bank, which held approximately 20% of the company's total cash [195]. - An immediate 10% change in interest rates would not have a material effect on the fair market value of the company's investment portfolio due to its low risk profile [208].

Assessment of geographic atrophy progression in the phase 3 OAKS and DERBY trials Allen Chiang, Sujata Sarda, Mark Burch, Min Tsuboi, Daniel Jones, and Ramiro Ribeiro The Association for Research in Vision and Ophthalmology Annual Meeting New Orleans, USA April 23–27, 2023 Phase 3 OAKS and DERBY trials: Design and key criteria Patients with GA secondary to AMD 1258 patients at 232 sites combined Randomized 2:2:1:1 Pegcetacoplan monthly (N=419) Pegcetacoplan EOM (N=420) Sham monthly (N=208) Sham EOM (N=211) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 | --- | --- | --- | |----------------------------------------------------------------------------|----------------------------- ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Adam Townsend - Chief Commercial Officer Cedric Francois - Co-Founder, President & Chief Executive Officer Federico Grossi - Co-Founder & Chief Medical Officer Meredith Kaya - Senior Vice President, Investor Relations & Strategic Finance Timothy Sullivan - Chief Financial Officer Conference Call Participants Tazeen Ahmad - BAML Jon Miller - Evercore Anupam Rama - JPMorgan Philip Nade ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend - Chief Commercial Officer Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Federico Grossi - Chief Medical Officer Conference Call Participants Madhu Kumar - Goldman Sachs Group Umer Raffat - Evercore Anupam Rama - JPMorgan Tazeen Ahmad - Bank of America Lyla Youssef - Cowen Steven Seed ...